Meeting
2019 ASCO Annual Meeting
Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors.
Authors
Manish R. Patel
Florida Cancer Specialists and Sarah Cannon Research Institute, Sarasota, FL
Manish R. Patel , Gerald Steven Falchook , Judy Sing-Zan Wang , Esteban Rodrigo Imedio , Sanjeev Kumar , Pejvack Motlagh , Kowser Miah , Ganesh M. Mugundu , Suzanne Fields Jones , David R. Spigel , Erika Paige Hamilton
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT02617277
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2562)
DOI
10.1200/JCO.2019.37.15_suppl.2562
Abstract #
2562
Poster Bd #
206
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
A phase II trial of AZD1775 plus carboplatin-paclitaxel in squamous cell lung cancer (SqCLC).
First Author: Bruna Pellini
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors.
First Author: Iwona A. Lugowska
Poster
2023 ASCO Annual Meeting
A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).
First Author: Mohamed Shanshal
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.
First Author: Jing Huang